Anika Therapeutics (ANIK) Stock News

Anika Therapeutics reported a strong fourth quarter with revenue growth of 11% to $39.6 million and full-year revenue growth of 6% to $156.2 million. Notable increases were seen in Osteoarthritis Pain Management, with revenues reaching $23.7 million (20% growth). The company commenced the limited market release of the RevoMotion Reverse Shoulder Arthroplasty System and fully launched the X-Twist Fixation System. Anika's Hyalofast product is nearing full enrollment in its pivotal Phase III trial, while the FDA has designated it as a Breakthrough Device. For 2023, Anika expects revenue between $158 million and $163 million, reflecting modest growth amid various product reclassifications.

Anika Therapeutics (NASDAQ: ANIK) has announced its participation in the Canaccord Genuity Musculoskeletal Conference in Las Vegas on March 7, 2023, at 3:00 p.m. PT (6:00 p.m. ET). The conference is aimed at showcasing advancements in early intervention orthopedics, a field where Anika specializes. A live audio webcast will be accessible via the Investor Relations section on Anika's official website, www.anika.com. Additionally, an audio archive of the session will be available afterward, providing further insights into the company's innovative products and strategies.

Anika Therapeutics (NASDAQ: ANIK) announced plans to release its fourth quarter and year-end 2022 financial results on March 6, 2023, after market close. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss these results and business highlights. Investors can access the call by dialing the provided numbers or through a live audio webcast on Anika's website. Anika Therapeutics focuses on joint preservation and orthopedic care, delivering innovative solutions in areas such as osteoarthritis and sports medicine. Further information and an accompanying slide presentation will be available online.

Anika Therapeutics (NASDAQ: ANIK) addressed a letter from Caligan Partners LP, highlighting their recent strategic discussions and growth initiatives. Over six months, Anika's Board engaged with Caligan eight times, emphasizing confidence in a strategy that expands its market opportunity from $1 billion to over $8 billion. The firm continues to leverage its leadership in osteoarthritis pain management, which supports investments in regenerative and joint preservation products. Anika's stock has risen approximately 40% since June 2022, outperforming the NASDAQ Composite by 42%. The fourth quarter and year-end financial results will be announced on March 6, 2023.

Caligan Partners LP, a significant shareholder of Anika Therapeutics (NASDAQ: ANIK), has publicly criticized the current board for strategic missteps and poor capital allocation, contributing to the company's underperformance. In a letter dated February 21, 2023, Caligan highlighted the substantial losses in Anika's joint preservation segment and the failure to leverage its viscosupplement portfolio effectively. They are advocating for a strategic review and have proposed three specific actions aimed at driving significant changes to enhance shareholder value.

Anika Therapeutics has launched the RevoMotion Reverse Shoulder Arthroplasty System, expanding its portfolio in the $800 million U.S. reverse shoulder market. The system features the industry's smallest diameter threaded glenoid baseplate, which enhances bone preservation and surgical flexibility. It aims to increase efficiency in operating rooms with streamlined instrument trays and is designed to meet a growing demand for shoulder arthroplasty procedures, projected at 200,000 for the U.S. in 2023. The limited market release is currently underway, with a full release expected in late 2023.

Anika Therapeutics reported a 2% revenue growth for Q3 2022, totaling $40.3 million. Key product segments included OA Pain Management at $25.7 million (down 2%) and Non-Orthopedic revenue at $2.8 million (up 27%). The company experienced a net loss of $4.2 million or $(0.29) per share, compared to net income of $0.6 million in Q3 2021. Notably, the Phase III trial for Cingal achieved primary endpoints, demonstrating superiority over steroid treatment. The Hyalofast trial is nearing full enrollment, and the company remains on track to meet FY2022 guidance.

Anika Therapeutics announced that Cingal met its primary endpoint in a Phase III study, showing superiority over steroid alone for osteoarthritis pain relief at 26 weeks. With a 71% mean pain improvement, Cingal combines hyaluronic acid with a steroid, and is already commercialized in over 35 countries. Anika plans to engage the FDA for U.S. approval and explore partnerships for Cingal's advancement in the U.S. and Asia. This study builds on prior Phase III results and positions Anika for significant market opportunities, addressing an unmet need for the 32 million osteoarthritis patients in the U.S.

Anika Therapeutics, Inc. (NASDAQ: ANIK) will release its third quarter 2022 financial results after market close on November 8, 2022. The company will host a conference call on the same day at 5:00 p.m. ET to discuss these results and highlight business developments. Interested parties can join via phone or listen to a live audio webcast on Anika's Investor Relations webpage. Anika focuses on innovative orthopedic care, particularly in joint preservation, leveraging hyaluronic acid and implant solutions.